Nang Quang Pharmaceutical Co. Ltd.

The drug is intended for adult patients who are ineligible for stem cell transplantation and suffer from intermediate-2 and high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) with 10–29% blasts in the bone marrow, as well as acute myeloid leukemia (AML) with varying blast levels (20–30% or over 30% depending on the classification).

Dosage form: lyophilisate for solution for injection

ATC: L01BC07